Woodline Partners LP lifted its holdings in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 235.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,848,802 shares of the company's stock after buying an additional 2,000,268 shares during the period. Woodline Partners LP owned approximately 2.26% of Humacyte worth $14,386,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vontobel Holding Ltd. acquired a new stake in Humacyte during the fourth quarter worth about $50,000. Petros Family Wealth LLC acquired a new position in shares of Humacyte in the fourth quarter valued at approximately $50,000. Syon Capital LLC purchased a new position in Humacyte in the fourth quarter worth approximately $54,000. ACT Wealth Management LLC purchased a new position in Humacyte in the fourth quarter worth approximately $57,000. Finally, Ameriprise Financial Inc. purchased a new position in Humacyte in the fourth quarter worth approximately $58,000. 44.71% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently issued reports on HUMA. HC Wainwright began coverage on shares of Humacyte in a research note on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target for the company. Wall Street Zen upgraded shares of Humacyte from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Tuesday, May 13th. Finally, Benchmark decreased their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $11.71.
Read Our Latest Stock Report on HUMA
Insider Transactions at Humacyte
In other Humacyte news, Director Kathleen Sebelius bought 50,000 shares of the business's stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the acquisition, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. The trade was a 121.34% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Dale A. Sander bought 20,000 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by insiders.
Humacyte Price Performance
Shares of NASDAQ:HUMA traded down $0.03 during trading on Tuesday, hitting $2.51. 2,208,537 shares of the company were exchanged, compared to its average volume of 3,769,308. The stock has a market capitalization of $388.57 million, a P/E ratio of -1.87 and a beta of 1.64. Humacyte, Inc. has a 12-month low of $1.15 and a 12-month high of $9.97. The firm's 50 day moving average price is $1.75 and its 200-day moving average price is $3.35.
Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, equities research analysts anticipate that Humacyte, Inc. will post -1.27 EPS for the current year.
Humacyte Profile
(
Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
